您的购物车当前为空
Y06036 是一种选择性 BET 抑制剂,具有抗肿瘤活性,可与 BRD4(1)溴结构域结合,Kd 值为 82 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Y06036 是一种选择性 BET 抑制剂,具有抗肿瘤活性,可与 BRD4(1)溴结构域结合,Kd 值为 82 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 113 | In Stock | |
| 5 mg | ¥ 239 | In Stock | |
| 10 mg | ¥ 398 | In Stock | |
| 25 mg | ¥ 690 | In Stock | |
| 50 mg | ¥ 1,090 | In Stock | |
| 100 mg | ¥ 1,790 | In Stock | |
| 200 mg | ¥ 2,590 | In Stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 273 | In Stock |
Y06036 相关产品
| 产品描述 | Y06036, a potent and selective BET inhibitor, can bind to the BRD4(1) bromodomain (Kd: 82 nM). |
| 靶点活性 | BRD4(1):82 nM (Kd, cell free) |
| 体外活性 | Y06036与BRD4(1)溴结构域结合,其Kd值为82 nM。Y06036在前列腺癌细胞系中强效抑制细胞增长、集落形成以及AR、AR调控基因和MYC的表达。 |
| 体内活性 | 小鼠在肿瘤体积达到约100 mm3时,随机分组并通过腹膜内(i.p.)给药,接受安慰剂或BET抑制剂Y06036(50 mg/kg,每周5次)治疗。在25天的治疗期间,Y06036表现出强大的抗肿瘤活性,肿瘤生长抑制(TGI)达到70%。 |
| 细胞实验 | LNCaP, C4-2B, 22Rv1, and VCaP prostate cancer cells were cultured in RPMI 1640 with 10% FBS at 37 °C and an atmosphere of 5% CO2. For cell viability, cells were seeded in 384-well plates at 500?1000 cells per well (optimum density for growth) in a total volume of 20 μL of media. After 12 h, 10 μL of chemical compounds with 2-fold or 3-fold serial dilution was added to each well with final concentration from 5 nM to 100 μM. The measurement was conducted 96 h after seeded for LNCaP, C4-2B, and 22Rv1 and 144 h after seeded for VCaP. Then, 25 μL of CellTiter-GLO reagents was added, and luminescence was measured on GLOMAX microplate luminometer, according to the manufacturer's instructions. The estimated in vitro half-maximal inhibitory concentration (IC50) values were calculated using Prism 6 software. |
| 动物实验 | Four-week-old male mice (strain: C.B-17/IcrHsd-Prkdcscid for C4-2B) were used for tumor inoculation. Each mouse was inoculated subcutaneously at the dorsal flank on both sides of the mice with C4-2B tumor cells (2 × 10^6 cells) in a mixture of 100 μL PBS and Matrigel (1:1). When the tumor volume reached approximately 100 mm3, the mice were randomized into groups (n = 5?7 per group) and then treated intraperitoneally (ip) with 100 μL of either vehicle or Y06036 and 7m (in a formulation of 15% Cremophor EL, Calbiochem, 82.5% PBS, and 2.5% DMSO) five times per week. The length (L) and width (W) of the tumor mass were monitored by calipers, and volume was expressed in mm3 calculated with the equation V = (π/6)(L × W2). Tumor growth inhibition (TGI) was calculated using the equation TGI = [1 ? (T ? T0)/(C ? C0)] × 100, wherein T and T0 are the mean tumor volumes on a specific experimental day and on the first day of treatment, respectively, for the test groups; and likewise C and C0 are the mean tumor volumes for the vehicle group. |
| 分子量 | 427.27 |
| 分子式 | C16H15BrN2O5S |
| CAS No. | 1832671-96-1 |
| Smiles | COc1cc2onc(C)c2cc1NS(=O)(=O)c1cc(Br)ccc1OC |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (234.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.36 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容